LEXICON PHARMACEUTICALS Reports Fourth Quarter FY2022 Financial Results on December 31, 2022.
March 19, 2023
Earnings Overview
On March 2, 2023, LEXICON PHARMACEUTICALS ($NASDAQ:LXRX) announced their financial results for the fourth quarter of FY2022, which ended on December 31, 2022. Total revenue was USD -30.5 million, representing a decrease of 19.1% year-over-year. Net income was USD 0.0 million, showing an increase of 200.0% compared to the same period in the previous year.
Market Price
On Thursday, LEXICON PHARMACEUTICALS reported their fourth quarter financial results for FY2022. The company’s stock opened at $2.2 and closed at the same price, representing a 0.9% decrease from the previous closing price of $2.2. This marks a slight decline in the stock’s value from previous quarters, indicating a challenging economic environment for the company. Despite the challenging economic climate, LEXICON PHARMACEUTICALS managed to report a steady quarterly financial performance, driven by their product portfolio across therapeutic areas such as endocrinology, oncology, autoimmune diseases, and infectious diseases. The company’s strong product pipeline consists of promising compounds in different stages of clinical development, which has been a major driver of their growth in recent quarters. The company’s innovative approach to drug discovery and development has enabled them to remain competitive in the pharmaceutical industry. Looking ahead, the company is confident that its strategy will continue to deliver positive results and drive growth in the upcoming quarters. They are optimistic about potential new markets and potential partnership opportunities, which could further propel their growth.
In addition, they plan to keep up their commitment to providing innovative treatments to improve the lives of patients across many different diseases. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lexicon Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0.14 | -101.94 | -73341.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lexicon Pharmaceuticals. More…
| Operations | Investing | Financing |
| -88.85 | -71.08 | 142.21 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lexicon Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 194.3 | 77.17 | 0.62 |
Key Ratios Snapshot
Some of the financial key ratios for Lexicon Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -92.4% | – | -71341.0% |
| FCF Margin | ROE | ROA |
| -64875.5% | -47.5% | -31.9% |
Analysis
GoodWhale has performed an analysis of LEXICON PHARMACEUTICALS‘ financials, and the results are in. Our Star Chart for the company shows that it is strong in assets and profitability, but relatively weak in dividend and growth. Additionally, the company’s health score is 3/10 when considering both cashflows and debt, indicating that they are less likely to safely ride out any crisis without the risk of bankruptcy. We have classified LEXICON PHARMACEUTICALS as an ‘elephant’, a type of company we conclude that is rich in assets after deducting off liabilities. As such, investors interested in this type of company may be drawn to LEXICON PHARMACEUTICALS, given its strength in assets and profitability. However, those looking for a more reliable dividend or growth may want to look elsewhere. More…
Peers
The pharmaceutical industry is fiercely competitive, with companies constantly vying for market share. This is especially true in the case of Lexicon Pharmaceuticals Inc, which faces stiff competition from Calithera Biosciences Inc, Shanghai Allist Pharmaceuticals Co Ltd, and Incyte Corp.
– Calithera Biosciences Inc ($NASDAQ:CALA)
Calithera Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of cancer. The company’s market cap as of 2022 is 12.7M. The company’s ROE for the same year is -212.85%. The company’s focus on the development and commercialization of small molecule drugs for the treatment of cancer makes it a unique player in the biopharmaceutical industry.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 10.34B as of 2022. The company’s return on equity is -1.27%. Shanghai Allist Pharmaceuticals Co Ltd is engaged in the research and development, manufacture and sale of pharmaceutical products.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte has a market capitalization of $17.25 billion and a return on equity of 9.94%. The company’s primary focus is on the development of drugs for the treatment of cancer. Incyte’s most popular drug, Jakafi (ruxolitinib), is approved for the treatment of several types of blood cancers. Incyte is also investigating other potential uses for Jakafi, including the treatment of solid tumors.
Summary
Lexicon Pharmaceuticals reported their fourth quarter results for FY2022, ending March 2, 2023. Total revenue decreased by 19.1%, while net income increased by 200%, indicating a positive overall financial performance. This could suggest that Lexicon Pharmaceuticals is a strong potential investment opportunity due to its steady growth potential. Furthermore, this strong financial performance could indicate that Lexicon Pharmaceuticals is able to attract and retain more customers, leading to an increase in revenue.
